Literature DB >> 22854670

Overview of the cancer vaccine field: are we moving forward?

Alex Kudrin1, Michael G Hanna.   

Abstract

Cancer immunotherapy has seen a tremendous number of failures and only few recent regulatory successes. This review is a first in a series dedicated to evaluate the status of current global clinical pipeline for cancer vaccines. Apart from specific areas of medical need which can be addressed by cancer vaccines, the analysis of the pipeline by clinical indication suggests that a disproportionately large number of candidates is currently developed in prostate, breast, lung cancer and melanoma with significant gap of candidates in remaining oncology indications. With potential offering and benefits that cancer immunotherapy could bring to patient community and society as a whole, we require new innovative R&D, improved Antigen Discovery programs and business models to fill serious gaps in cancer vaccine R&D pipeline.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22854670      PMCID： PMC3551888          DOI： 10.4161/hv.20474

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  5 in total

1.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

2.  Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.

Authors:  Rebecca Siegel; Elizabeth Ward; Otis Brawley; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2011-06-17       Impact factor: 508.702

3.  Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.

Authors:  Nikhil Wagle; Caroline Emery; Michael F Berger; Matthew J Davis; Allison Sawyer; Panisa Pochanard; Sarah M Kehoe; Cory M Johannessen; Laura E Macconaill; William C Hahn; Matthew Meyerson; Levi A Garraway
Journal:  J Clin Oncol       Date:  2011-03-07       Impact factor: 44.544

4.  The genomic landscapes of human breast and colorectal cancers.

Authors:  Laura D Wood; D Williams Parsons; Siân Jones; Jimmy Lin; Tobias Sjöblom; Rebecca J Leary; Dong Shen; Simina M Boca; Thomas Barber; Janine Ptak; Natalie Silliman; Steve Szabo; Zoltan Dezso; Vadim Ustyanksky; Tatiana Nikolskaya; Yuri Nikolsky; Rachel Karchin; Paul A Wilson; Joshua S Kaminker; Zemin Zhang; Randal Croshaw; Joseph Willis; Dawn Dawson; Michail Shipitsin; James K V Willson; Saraswati Sukumar; Kornelia Polyak; Ben Ho Park; Charit L Pethiyagoda; P V Krishna Pant; Dennis G Ballinger; Andrew B Sparks; James Hartigan; Douglas R Smith; Erick Suh; Nickolas Papadopoulos; Phillip Buckhaults; Sanford D Markowitz; Giovanni Parmigiani; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein
Journal:  Science       Date:  2007-10-11       Impact factor: 47.728

5.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

Authors:  Marco Gerlinger; Andrew J Rowan; Stuart Horswell; James Larkin; David Endesfelder; Eva Gronroos; Pierre Martinez; Nicholas Matthews; Aengus Stewart; Charles Swanton; M Math; Patrick Tarpey; Ignacio Varela; Benjamin Phillimore; Sharmin Begum; Neil Q McDonald; Adam Butler; David Jones; Keiran Raine; Calli Latimer; Claudio R Santos; Mahrokh Nohadani; Aron C Eklund; Bradley Spencer-Dene; Graham Clark; Lisa Pickering; Gordon Stamp; Martin Gore; Zoltan Szallasi; Julian Downward; P Andrew Futreal
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245
  5 in total
  9 in total

Review 1.  Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).

Authors:  Ashish Patel; Chia Yin Goh; Matthew Ho; Maria Moscvin; Li Zhang; Giada Bianchi
Journal:  Leukemia       Date:  2020-10-12       Impact factor: 11.528

2.  A Therapeutic Whole-Tumor-Cell Vaccine Covalently Conjugated with a TLR7 Agonist.

Authors:  Huju Chi; Yue Hao; Xia Wang; Li Tang; Yongqiang Deng; Xianxiong Chen; Feng Gao; Ou Sha; Guangyi Jin
Journal:  Cells       Date:  2022-06-21       Impact factor: 7.666

3.  A whole-cell tumor vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumor cells and cancer-associated fibroblasts.

Authors:  Meihua Chen; Rong Xiang; Yuan Wen; Guangchao Xu; Chunting Wang; Shuntao Luo; Tao Yin; Xiawei Wei; Bin Shao; Ning Liu; Fuchun Guo; Meng Li; Shuang Zhang; Minmin Li; Kexing Ren; Yongsheng Wang; Yuquan Wei
Journal:  Sci Rep       Date:  2015-09-23       Impact factor: 4.379

Review 4.  A key to the backdoor into the castle: The clinical ramifications of immunoediting driven by antigenic competition.

Authors:  M G Hanna; Jason D Howard
Journal:  Hum Vaccin Immunother       Date:  2017-03-24       Impact factor: 3.452

Review 5.  Bacterial outer membrane vesicles as a candidate tumor vaccine platform.

Authors:  Shuming Wang; Jiayi Guo; Yang Bai; Cai Sun; Yanhao Wu; Zhe Liu; Xiaofei Liu; Yanfeng Wang; Zhigang Wang; Yongmin Zhang; Huifang Hao
Journal:  Front Immunol       Date:  2022-09-09       Impact factor: 8.786

6.  Identification and enhancement of HLA-A2.1-restricted CTL epitopes in a new human cancer antigen-POTE.

Authors:  Yi-Hsiang Huang; Masaki Terabe; C David Pendleton; Deborah Stewart Khursigara; Tapan K Bera; Ira Pastan; Jay A Berzofsky
Journal:  PLoS One       Date:  2013-06-04       Impact factor: 3.240

Review 7.  Cancer vaccines: are we there yet?

Authors:  Michael G Hanna
Journal:  Hum Vaccin Immunother       Date:  2012-08-01       Impact factor: 3.452

8.  A co-stimulatory trap set by myeloid leukemia cells.

Authors:  Gunes Esendagli
Journal:  Oncoimmunology       Date:  2013-05-23       Impact factor: 8.110

Review 9.  Design of Outer Membrane Vesicles as Cancer Vaccines: A New Toolkit for Cancer Therapy.

Authors:  Yingxuan Zhang; Zheyan Fang; Ruizhen Li; Xiaotian Huang; Qiong Liu
Journal:  Cancers (Basel)       Date:  2019-09-06       Impact factor: 6.639
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.